Ibogainalog
Ibogainalog, also known as 9-methoxyibogaminalog, is a non-selective serotonin receptor modulator, serotonergic psychedelic, and psychoplastogen of the ibogalog group related to the iboga alkaloid ibogaine but with a simplified chemical structure.
Pharmacology
Pharmacodynamics
Ibogainalog acts as a non-selective serotonin receptor modulator, including as an agonist of the serotonin 5-HT1B, 5-HT1F, 5-HT2A, and 5-HT6 receptors, as an agonist or antagonist of the serotonin 5-HT2B and 5-HT2C receptors, and as an inverse agonist of the serotonin 5-HT7 receptor. Unlike noribogaine, IBG shows no activation of the opioid receptors or κ-opioid receptor agonism. In addition to its actions at serotonin receptors, IBG weakly inhibits certain nicotinic acetylcholine receptors. The drug also acts as a relatively weak serotonin reuptake inhibitor.The drug produces the head-twitch response in animals and hence shows psychedelic-like effects. However, it has reduced and relatively weak hallucinogen-like effects compared to 5-MeO-DMT. Conversely, tabernanthalog, a simplified analogue of tabernanthine and positional isomer of IBG, appears to be completely non-hallucinogenic. IBG shows comparable psychoplastogenic activity to ibogaine. In contrast to ibogaine, IBG and TBG appear to have much less or no potential for cardiotoxicity secondary to hERG inhibition. However, TBG showed a better overall safety profile than IBG and was selected for development instead of IBG. IBG shows analgesic effects against neuropathic pain and visceral pain in animals that appear to be mediated by serotonin 5-HT2A receptor activation.
In early animal studies, ibogainalog was described as having enhanced tryptamine-like, tremorogenic, and sedative effects compared to ibogaine. It was also said to have chlorpromazine-like effects.